This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medical Education Resources and HealthScience Media, Inc. Medical Education Resources is accredited by the ACCME to provide continuing medical education for physicians.
Medical Education Resources designates this live activity for a maximum of 27.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP (American Academy of Family Physicians) Credit
Pending approval from the American Academy of Family Physicians
Nursing Credit (ANCC)
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This CE activity provides 27.5 contact hours of continuing nursing education.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 27.5 contact hours.
AANP (American Academy of Nurse Practitioners) Credit
Pending approval from the American Academy of Nurse Practitioners
Registered Dietitian Credit
Medical Education Resources is an accredited CPE provider for the Commission on Dietetic Registration.
Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 27.5 contact hours (2.75 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Program Number – 0816-9999-14-002-L01-P)
Attention Certified Diabetes Educators: The 2014 Cardiometabolic Health Congress (CMHC) is accredited by Medical Education Resources (MER). MER is accredited by the ACCME, ANCC, ACPE, and the CDR to provide continuing medical education. All of these accredited organizations are recognized by the AADE when applying for CDE renewal of certification or for initial certification. For more information please visit Recognized Provider List | NCBDE
Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
As additional symposia are added the number of CME/CE credits will be updated.
Statement of Need
The ever-increasing presence of cardiometabolic risk continues to be a major challenge for health care professionals in the United States. The prevalence of most cardiometabolic risk factors – especially hypertension, diabetes, and obesity – continues to rise. In the years ahead, American physicians should expect to treat unprecedented numbers of patients at high risk for morbidity and mortality from cardiovascular disease. In 2000, approximately 32% of U.S. adults had the metabolic syndrome, a constellation of cardiometabolic risk factors including excessive abdominal fat, insulin resistance, dyslipidemia, and hypertension. In more recent years that figure has climbed to 34%, and it may even be as high as 38%, depending on the criteria used to define the syndrome.
Patients with multiple cardiometabolic risk factors have twice the likelihood of developing and dying from cardiovascular disease and more than seven times the risk of developing diabetes, compared to those with no cardiometabolic risk factors. As the number of these patients increases, the burden of cardiovascular disease can be expected to increase in the United States as well. Unfortunately, cardiovascular disease already affects approximately 82.6 million U.S. adults and is the leading cause of U.S. deaths. According to the American Heart Association, cardiovascular disease causes more than 800,000 deaths each year – more than cancer and accidents combined. This is an average of more than 2,200 deaths per day, or one death every 39 seconds.
Health care professionals play a major role in stemming the future burden of cardiovascular disease, diabetes, and associated comorbidities by employing aggressive strategies for the early identification and comprehensive management of patients presenting with multiple cardiometabolic risk factors. The 2014 Cardiometabolic Health Congress will translate the latest cutting-edge medical research into practical, clinical approaches for preventing, delaying, and managing cardiovascular and metabolic risk. The goal is to provide the medical community with evidence-based interventions to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk.
To improve patient outcomes through early identification and intervention strategies for patients with, or at risk of developing, diabetes and cardiovascular disease.
Target Audience & Learning Objectives
The CMHC is designed for advanced-level clinicians responsible for the prevention, diagnosis, and management of cardiometabolic risk.
At the end of the congress, participants will be able to:
- Explain the interrelationships among the various cardiometabolic risk factors, their impact on cardiovascular health, and their common comorbidities.
- Translate evidence-based strategies for prevention, screening, and treatment of cardiometabolic risk factors and their comorbidities to their clinical practice.
- Identify which interventions, including lifestyle changes and various drugs in combination, are most appropriate for particular patients based on their risk profiles.
- Identify how novel and emerging therapies can be integrated into clinical practice to reduce morbidity and mortality from cardiovascular and metabolic disease.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, HealthScience Media, Inc and/or the various industry supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, HealthScience Media, Inc. and/or the various industry supporters. MER’s ANCC accreditation status does not imply endorsement by MER or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.